Tests mevrometostat with enzalutamide in men with advanced prostate cancer
Tests mevrometostat plus enzalutamide, compared with placebo, in men with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Key facts
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guilin, Hangzhou, Hohhot, Huai'an, Jiaxing, Jinan, Nanjing, Nantong, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Tianjin, Weifang, Wenzhou, Wuhan, Wuhu, Xi'an, Xi’an, Xinxiang, Yantai, and Zhengzhou, ChinaSee the 30 sites
- Phase
- Phase 3
Where in China
- Cancer Hospital Chinese Academy of Medical ScienceBeijing, ChinaTaking people
- Peking University Third HospitalBeijing, ChinaTaking people
- Hunan Cancer HospitalChangsha, ChinaTaking people
- West China Hospital，Sichuan UniversityChengdu, ChinaTaking people
- Fujian Cancer HospitalFuzhou, ChinaTaking people
- Guangzhou First People's HospitalGuangzhou, ChinaTaking people
- The Second Affiliated Hospital of Guilin Medical UniversityGuilin, ChinaTaking people
- Sir Run Run Shaw Hospital Zhejiang University School of MedicineHangzhou, ChinaTaking people
- Inner Mongolia People's HospitalHohhot, ChinaTaking people
- Huai'an First People's HospitalHuai'an, ChinaTaking people
- The First Hospital Of JiaxingJiaxing, ChinaTaking people
- Shandong Provincial HospitalJinan, ChinaTaking people
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaTaking people
- Nantong Tumor HospitalNantong, ChinaTaking people
- The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
- Tongji Hospital of Tongji UniversityShanghai, ChinaTaking people
- The Second Affiliated Hospital of Shantou University School of MedicineShantou, ChinaTaking people
- First Affiliated Hospital of China Medical UniversityShenyang, ChinaTaking people
- The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
- The Second Hospital of Tianjin Medical UniversityTianjin, ChinaTaking people
- Weifang People's HospitalWeifang, ChinaTaking people
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
- Wannan Medical College Yijishan HospitalWuhu, ChinaTaking people
- Shaanxi Provincial People' HospitalXi'an, ChinaTaking people
- The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaTaking people
- The Third Affiliated Hospital of Xinxiang Medical UniversityXinxiang, ChinaTaking people
- Yantai Yuhuangding HospitalYantai, ChinaTaking people
- Henan Cancer HospitalZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06629779EU 2024-511652-40-00
- Record updated
- 30 October 2026
- Original description
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Inclusion: Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features; Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan; Progressive disease in the setting of medical or surgical castration; ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.
Exclusion: Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery; Participants must be treatment naïve at the mCRPC stage, eg, no cytotoxic chemotherapy, radio-ligand therapy (i.e. 177Lu- PSMA-617), CDK4/6 inhibitors, 5-alpha reductase inhibitors for prostate cancer in any setting, androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment with the following exceptions:; Treatment with first-generation antiandrogen (ADT) agents, estrogens, progestins, cyproterone acetate; Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion; Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer); Clinically significant cardiovascular disease; Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure; Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy with a few exceptions; Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that make the participant inappropriate for the study; Inadequate organ function.